A supplement brand prepares to launch a new capsule line. The contract manufacturer holds valid halal certification, the formula contains nothing obviously animal-derived, and the marketing artwork already carries a halal claim. Nobody in the room has checked whether the finished product is registered with the Drug Control Authority, and nobody has opened a halal file for the product itself. Two approvals are missing. Only one of them is about halal.
This is the structural mistake that separates health products from food and cosmetics. A biscuit manufacturer deals mainly with one approval pathway. A supplement, traditional medicine or pharmaceutical manufacturer deals with two, they are issued by different authorities, they ask different questions, and in Malaysia they run in a fixed order. Getting that order wrong wastes months.
Two authorities, two different questions
In Malaysia, medicines and health supplements are regulated under the Control of Drugs and Cosmetics Regulations 1984. The Drug Control Authority, supported by the National Pharmaceutical Regulatory Agency, decides whether a product may be sold at all. Registered products receive a registration number beginning with MAL, which must appear on the label. A foreign company cannot hold that registration directly; it must appoint a locally registered agent to act as the product registration holder.
Halal certification asks a separate question, and the Department of Islamic Development Malaysia (JAKIM) administers a dedicated pharmaceutical scheme for it. The technical reference is the Malaysian Standard MS 2424, revised in 2019 as Halal Pharmaceuticals: General Requirements, which the 2019 revision widened to cover vaccine products. The standard looks across materials, premises, equipment, personnel, processing, packaging, storage and distribution — not only at the ingredient list.
The practical consequence is sequencing. A product that has not cleared medicines registration is not in a position to be assessed under the pharmaceutical halal scheme, because there is no lawfully marketable product to certify. Brands that start with the halal application usually discover this at the document-check stage, after the formulation is locked and the packaging has been printed.
Where halal risk actually concentrates in a formulation
Health products carry a different risk profile from food. The ingredients most likely to stall an assessment are rarely the headline actives. They are the ones nobody markets:
- Capsule shells. Gelatin is the single most scrutinised input in the category. Its acceptability depends on the source animal, the slaughter and processing conditions, and the documentation the supplier can produce. Plant-derived and marine alternatives exist, but switching shells is a formulation change, not a procurement change.
- Excipients and processing aids. Lubricants, flow agents, coatings, emulsifiers and softeners frequently derive from fats that may be animal or vegetable in origin. The chemical name on the specification sheet usually does not say which.
- Fermentation-derived and enzyme-derived materials. The question extends past the final molecule to the growth media and processing inputs used to produce it.
- Solvents and carriers. Materials used in extraction, granulation or flavouring need a documented origin and process history, and treatment of these varies between jurisdictions and certification bodies.
- Coatings, inks and primary packaging. Materials in direct contact with the dosage form fall inside the scope of the assessment.
In every one of these cases, the determination is not made by the brand. Whether a specific material is acceptable depends on its actual source, the applicable standard, and the assessment of the certifying authority in the market concerned. What a manufacturer controls is the quality of the evidence it can put in front of that authority — which is why documentation, and not opinion, is the real preparation work. The same discipline applies when a business later changes an ingredient or supplier after certification has been granted.
Indonesia is running on a different clock
Indonesia treats health products as a separate phase in its mandatory halal timetable, and the sub-category a product falls into determines the deadline. Under the implementing regulations of the Halal Product Assurance Law, traditional medicines and food supplements — together with cosmetics, chemical products, and Class A medical devices — become subject to mandatory halal certification and labelling from 17 October 2026. Over-the-counter medicines and Class B medical devices follow on 17 October 2029, and prescription medicines and Class C medical devices on 17 October 2034. Presidential Regulation No. 6 of 2023 sets out the halal certification framework for medicines, biological products and medical devices, with narcotic and psychotropic medicines exempt.
Certification in Indonesia is issued by BPJPH, not by JAKIM, and a Malaysian certificate does not automatically satisfy the Indonesian requirement. Exporters in the food categories are already working through the same date, and the groundwork overlaps closely with what halal exporters should have in place before Indonesia’s October 2026 deadline.
| Market | Medicines and supplement approval | Halal certification | Key reference |
|---|---|---|---|
| Malaysia | Drug Control Authority registration via NPRA, under the Control of Drugs and Cosmetics Regulations 1984 | JAKIM pharmaceutical scheme | MS 2424:2019 |
| Indonesia | Marketing authorisation under the national medicines and supplements regime | BPJPH certification | Halal Product Assurance Law and its implementing regulations; Presidential Regulation No. 6/2023 |
Manufacturers selling into other Asian markets should confirm the position with the relevant national authority rather than assuming the Malaysian or Indonesian model applies. Requirements, recognised certification bodies and validity periods differ, and recognition status can change.
A readiness checklist before applying
Most rejected or delayed applications fail on the same items. Before submitting anything, work through this sequence:
- Confirm product classification first. Whether a product is a health supplement, a traditional medicine, a quasi-medicine or a registrable drug changes both the medicines pathway and, in Indonesia, the deadline that applies.
- Secure the medicines approval. Registration or notification with the relevant authority comes before, not alongside, the halal application in Malaysia.
- Build a complete raw material file. Every input, including excipients, capsule shells, coatings and processing aids, needs a named manufacturer, a declared origin and valid supporting documentation from a certification body recognised in the target market.
- Appoint and train the internal halal personnel. The Malaysian scheme expects a designated Halal Executive with the corresponding certificate and appointment letter, alongside a documented halal assurance system.
- Verify the manufacturing site, not just the brand. If production is outsourced, the site’s certificate must cover the relevant scheme, the relevant lines and the relevant product. This is the same verification discipline brands need when outsourcing production to a contract manufacturer.
- Map segregation and cleaning. Shared equipment, shared warehousing and shared transport all fall within scope, and the cleaning validation evidence has to exist before an auditor asks for it.
- Freeze the artwork last. Halal marks and claims are governed by the certification rules of the issuing authority. Printing ahead of approval is how compliant products end up with non-compliant packaging. The boundaries of what businesses can and cannot say without certification apply to supplements exactly as they do to food.
What each approval proves — and what it does not
The category attracts a particular kind of confusion, because health products carry claims about the body. It is worth being exact about what each document establishes.
| Approval or recognition | What it establishes | What it does not establish |
|---|---|---|
| Medicines or supplement registration | That the product has been assessed by the medicines regulator and may lawfully be marketed | Halal status |
| Halal certification (JAKIM, BPJPH or another competent authority) | Compliance with the applicable halal requirements of that authority, for the scope stated on the certificate | Safety, efficacy, therapeutic benefit or market performance |
| Business award | Recognition under the criteria of the award programme | Halal compliance or regulatory approval |
| Asia Record recognition | An exceptional, objectively measurable achievement that has been assessed and verified | Halal compliance, regulatory approval or product efficacy |
Halal certification says nothing about whether a supplement works. That question belongs entirely to the medicines regulator and to the clinical and quality evidence behind the registration. Treating a halal mark as a health endorsement is a marketing error with regulatory consequences.
The same clarity is useful in the opposite direction. Halal pharmaceuticals is a substantial sector in its own right — DinarStandard’s State of the Global Islamic Economy Report 2025/26 puts global Muslim spending on halal pharmaceuticals at US$112 billion in 2024, with a forecast of US$146 billion by 2029 — and manufacturers competing in it produce a great deal of measurable output: batch throughput, registered product counts, export destinations, capacity expansion. Where a certified manufacturer achieves something genuinely exceptional and can evidence it with verifiable records, that achievement belongs in a different category of recognition from its certificates, and can be assessed on its own terms through applying for Asia Record recognition. It is a separate process with separate criteria, and it neither substitutes for nor reinforces a halal certificate.
Start with classification, not with the logo
Almost every avoidable delay in this category traces back to the same moment: a brand decided what its packaging would say before it decided what its product legally is. Classify the product, clear the medicines pathway, assemble the ingredient evidence, and apply for halal certification against a formulation that is already locked and lawful. For anyone selling supplements or traditional medicines into Indonesia, that work needs to be well advanced now rather than in the weeks before 17 October 2026.
